Genetic insights into the association between inflammatory bowel disease and Alzheimer's disease

Lu Zeng[1], Charles C. White[1], David A. Bennett[2], Hans-Ulrich Klein[1], Philip L. De Jager[1*]

[1]Center for Translational and Computational Neuroimmunology, Department of Neurology and the Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University Irving Medical Center, New York, NY, USA.

[2]Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.

Abstract

Myeloid cells, including monocytes, macrophages, microglia, dendritic cells and neutrophils are a part of innate immune system, playing a major role in orchestrating innate and adaptive immune responses. Both Alzheimer's disease (AD) and inflammatory bowel disease (IBD) susceptibility loci are enriched for genes expressed in myeloid cells, but it is not clear whether these myeloid risk factors are shared between the two diseases. Leveraging results of genome-wide association studies, we investigated the causal effect of IBD (including ulcerative colitis (UC) and Crohn's disease (CD)) variants on AD and its endophenotypes. Microglia and monocyte expression Quantitative Trait Locus (eQTLs) were used to examine the functional consequences of IBD and AD variants. Our results revealed distinct sets of genes and pathways of AD and IBD susceptibility loci. Specifically, AD loci are enriched for microglial eQTLs, while IBD loci are enriched for monocyte eQTLs. However, we also found that genetically determined IBD is associated with a protective effect against AD ($p<0.03$). Yet, a genetic propensity for the CD subtype is associated with increased amyloid accumulation (beta=7.14, p-value=0.02) and susceptibility to AD. Susceptibility to UC was associated with increased deposition of TDP-43 (beta=7.58, p-value=6.11×10^{-4}). The relation of these gastrointestinal inflammatory disease to AD is therefore

complex; while the different subsets of susceptibility variants preferentially affect different myeloid cell subtypes, there do appear to be certain shared pathways and the possible protective effect of IBD susceptibility on the risk of AD which may provide therapeutic insights.

Keywords: Inflammatory bowel disease, Alzheimer's disease, AD endophenotypes, GWAS, eQTL, Mendelian randomization, PheWAS

Introduction

Myeloid cells (i.e., monocytes, macrophages, microglia, dendritic cells and neutrophils), are an important component of the innate immune system and also play critical roles in tissue development, homeostasis, disease, and repair. Their regulatory architecture is gradually emerging (1, 2) and includes a number of different transcriptional programs, many of which are specialized for the tissue context in which a given myeloid cell finds itself. Dysfunction in the immunoregulatory roles of these cells may play a part in the pathogenesis of a subset to patients with inflammatory bowel disease (IBD). IBD, including its two major subtypes of ulcerative colitis (UC) and Crohn's disease (CD), is a chronic gastrointestinal inflammatory disease whose etiology remains poorly understood and leads to recurrent attacks of acute inflammation over more chronic changes (3). Genetic studies have noted a propensity for IBD variants to influence gene expression in monocytes (4, 5), consistent with the observations that different bone marrow-derived macrophages found in the intestinal epithelium and perhaps those in the enteric nervous system contribute to these acute and chronic inflammatory changes (6). By contrast, microglia, the resident myeloid cells in the central nervous system (CNS), arise from primitive yolk-sac emigrants that infiltrate the developing neurectoderm that will differentiate into the central nervous system (CNS) (7). Activation of microglia in the human brain, concentrated around amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), is a prominent feature of Alzheimer's disease (AD) pathology (8). AD is the most common aging-related neurodegenerative disease and is the most common cause of dementia (9), and the majority of AD susceptibility loci contain genes expressed by microglia and monocytes (8, 10, 11). Thus, both AD and IBD susceptibility appear to involve perturbation of myeloid cell function. Epidemiologic studies have further reported that patients with IBD had a more than two-fold increase in the risk of developing dementia (12).

24 Further, dementia was diagnosed around 7 years earlier in people with IBD than in those without
25 (13). However, more robust evidence is needed to understand whether IBD and AD (instead of the
26 broader diagnostic grouping of "dementia") are truly linked.
27
28 Here, we leveraged existing IBD and AD genome-wide association studies (GWAS), and
29 microglial and monocyte expression Quantitative Trait Locus (eQTL) datasets (11, 14, 15) to
30 examine the extent to which functional consequences of IBD and AD risk variants may be shared
31 or distinct. We investigated the genetic effect of IBD on AD and AD endophenotypes, and the
32 genetic correlation among IBD, AD and other disease traits. Our results indicate that (1) Overall,
33 IBD loci are different from AD loci, indicating separate genetic underpinnings for the two
34 conditions that affect different aspects of myeloid function. (2) AD risk variants displayed a
35 enrichment in microglia eQTLs; in contrast, risk variants associated with IBD and UC were
36 enriched in monocyte eQTLs, highlighting the context-specific effects of these variants. (3)
37 Genetically determined IBD was consistently linked to a reduced risk of AD, suggesting a
38 protective genetic influence. (4) Conversely, a propensity for the IBD subtype of CD was
39 associated with a higher risk of AD, possible due to its positive effect on the accumulation of
40 amyloid within cerebral blood vessles, and genetic susceptibility for UC was found associated with
41 increased TDP-43 burden. Thus, we find that these two clinically distinct entities – IBD and AD
42 – have important contributions from myeloid cells in the early functional consequences of
43 susceptibility variants that are largely distinct even if they affect the same cell types; nonetheless,
44 there may be a modest genetic interaction between these two groups of susceptibility variants.
45

46 **Materials and methods**

47 **IBD and AD variants collection**

48 A recent study reported a combination of 241 known SNPs with the smallest p-value in fifteen
49 studies associated with IBD/UC/CD (16). We extracted the GWAS summary statistics (e.g., effect
50 allele, effect size and p-value) from this study, p-values smaller than 5×10^{-8} were retained for the
51 following analyses, resulting in 81 IBD risk variants, 18 CD risk variants and 15 UC risk variants
52 (**Supplementary Table S1**).

53

54 For AD variants, previous study identified 38 independent AD risk loci from 90,338 cases (46,613
55 proxy) and 1,036,225 controls (318,246 proxy) (17), which were all reached genome-wide
56 significance, with $p \leq 5\times10^{-8}$ were kept (**Supplementary Table S2**).

57

58 **AD endophenotypes**

59 Ten AD endophenotypes were used in omnibus test and Phenome-wide association studies
60 (PheWAS) analysis, which were AD pathologies measurement from 2,409 ROSMAP participants
61 (18) (details can be seen in **Supplementary Table S3**). For instance, cogng_demog_slope, is the
62 random slope of global cognition that estimated person-specific rate of change in the global
63 cognition variable over time. It comes from a linear mixed effects model with global cognition as
64 the longitudinal outcome. The model controls for age at baseline, sex, and years of education.
65 amyloid_sqrt is the amyloid beta protein identified by molecularly-specific immunohistochemistry
66 and quantified by image analysis. Value is percent area of cortex occupied by amyloid beta. Mean
67 of amyloid beta score in eight regions (https://www.radc.rush.edu/docs/var/variables.htm). For
68 these 2,409 ROSMAP participants, their age at death ranged from 66yrs to 108yrs, with an average
69 of 89.5yrs (SD=±6.53), among them 718 were male, and 1,691 were female.

70

71 **eQTL data**

72 Monocyte cis-eQTL was downloaded from EMBL-EBI eQTL catalogue
73 (https://www.ebi.ac.uk/eqtl/) (14), which aims to provide uniformly processed gene expression
74 from all available public studies on human. The monocyte RNA-seq data was originally from
75 BLUEPRINT study (https://www.blueprint-epigenome.eu/) (15), based on 197 European
76 individuals, generated from whole blood. More details can be found at
77 https://www.ebi.ac.uk/eqtl/Methods/.

78

79 Microglia single-nucleus RNA sequencing data was generated from the dorsolateral prefrontal
80 cortex (DLPFC) of 424 ROSMAP (the Religious Order Study and the Rush Memory Aging
81 Project). Both studies are harmonized and include older individuals tested annually all of who
82 agreed to brain donation. They were approved by an Institutional Review Board of Rush University
83 Medical Center. All participants signed informed and repository consents, and an Anatomical Gift
84 Act. Matrix eQTL (19) version 2.3 method was then used to identify cis-eQTLs with 1 MB of the
85 transcription start site of each measure gene. More details can be found in our recent work (11). In
86 this study, we only kept the eQTL-eGene pairs with Bonferroni-Hochberg (BH) p-value<0.05,
87 resulting in 925,472 monocyte eQTL-eGene pairs, and 100,578 microglia eQTL-eGene pairs.

88

89 **Colocalization analysis**

90 The COLOC package (version 5.1.0) was applied to test the approximate Bayes factor (ABF)
91 colocalization hypothesis, which assumes a single causal variant. Under ABF analysis, the
92 association of a trait with a SNP is assessed by calculating the posterior probability (value from 0

93 to 1), with the value of 1 indicating the causal SNP. In addition, the ABF analysis has 5 hypotheses,
94 where, PP.H0.abf indicates there is neither an eQTL nor a GWAS signal at the loci; PP.H1.abf
95 indicates the locus is only associated with the GWAS; PP.H2.abf indicates the locus is only
96 associated with the eQTL; PP.H3.abf indicates that both the GWAS and eQTL are associated but
97 to a different genetic variant; PP.H4.abf indicates that the eQTL and the GWAS are associated to
98 the same genetic variant. With the posterior probability of each SNP and aiming to find the casual
99 variants between the GWAS and eQTL, we focused on extracting the PP.H4 value for each SNP
100 in our study.
101
102 For GWAS studies, we used the reported lead SNPs for each trait. For example, 38 AD risk loci,
103 81 IBD risk variants, 19 CD risk loci and 15 UC risk variants as we mentioned above. For each
104 locus, we searched for the eSNPs that are within 500 kb of the lead SNP, and listed eGenes that
105 were paired with the eSNP in microglia and monocyte eQTL datasets (15, 20). We then obtained
106 the eGenes cis-eQTL output around the lead eSNP within 1 Mbp window size. In addition, we
107 extracted GWAS summary statistics around the reported IBD/CD/UC lead SNP. At last, we
108 conducted COLOC for respective pair of eGene-eQTL and eSNP-GWAS.
109
110 **Omnibus test**
111 PLINK/1.9 –score (21) was used to calculate the polygenic risk score (PRS) of 81 IBD/19 CD/15
112 UC risk on 2,409 ROSMAP donors. We then applied a generalized linear regression model using
113 the R "glm" function to conduct the association test between the impact of IBD/CD/UC risk on
114 ten AD endophenotypes (details can be seen in **Supplementary Table S3**). Adjusting for the
115 covariates of age at death, sex and education years.

116

117 **PheWAS analysis**

118 Phenome-wide association studies (PheWAS) was further used to test the associations between 81
119 IBD/19 CD/ 15 UC risk variants (exposure) and ten AD endophenotypes (outcome), using the R
120 PheWAS package (22), adjusting for age at death, sex and education years. We used a linear
121 regression model giving the numeric phenotype outcomes. We established significance using an
122 FDR corrected *P*-value, accounting for ten AD endophenotypes.

123

124 **Mendelian randomization**

125 We performed Generalized Summary-data-based Mendelian Randomization (GSMR) (23)
126 analyses between IBD (exposure), including CD (exposure) and UC (exposure) on AD (outcome)
127 of European descent using GWAS summary statistics, implemented in GCTA software (v1.93.1f
128 beta). The instrumental variables were selected by a clumping procedure internal to the GSMR
129 software with parameters: --gwas-thresh 5×10^{-8} --clump-r2 0.05. The HEIDI-outlier test was
130 applied to test for horizontal pleiotropy ($P_{\mathrm{HEIDI}} < 0.01$). For comparison, we performed two-sample
131 MR analysis (2SMR) with the inverse-variance-weighted regression model and Egger regression
132 model, implemented via the TwoSampleMR R package (24).

133

134 **LD score regression (LDSC)**

135 LDSC (25) bivariate genetic correlations attribute to genome-wide SNPs (r_g) were estimated with
136 eleven human disease traits from published GWASs, including three IBD associated traits (IBD
137 (N_{cases} =25,042, $N_{controls}$=34,915), CD (N_{cases} =12,194; $N_{controls}$=28,072) and UC ((N_{cases}=12,366;
138 $N_{controls}$=33,609)) (16), three neurodegenerative disorders: AD (N_{cases}=90,338; $N_{controls}$=1,036,225)

139 (17), ALS (N_{cases}=27,205; $N_{controls}$=110,881) (26) and Parkinson's disease (PD) (N_{cases}=37,688;
140 N_{cases_proxy}= 18,618; $N_{controls}$=1,400,000) (27), another inflammatory diseases, multiple sclerosis
141 (MS) (N_{cases}=47,429; $N_{controls}$=68,374) (28) and a metabolic disease type 2 diabetes (T2D)
142 (N_{cases}=77,418; N_{controls}=356,122) (29) and three psychiatric disorders: bipolar disorder (BD)
143 (N_{cases}=41,917; N_{controls}=371,549) (30), major depressive disorder (MDD) (N_{cases}=170,756;
144 N_{controls}=329,443) (31) and schizophrenia (SCZ) (N_{cases}=76,755; N_{controls}=243,649) (32). Adjusting
145 for the number of traits tested, the FDR *P*-value threshold (FDR<=0.05) was used to define
146 significant genetic correlations.
147

148 ## Results

149 **Cell state specificity of IBD and AD**

150 To understand the functional consequences and potential interactions of IBD and AD susceptibility
151 loci, we compiled a list of 81 IBD risk variants, 19 CD risk variants and 15 UC risk variants
152 (meeting a threshold of genome-wide significance, $p \leq 5 \times 10^{-8}$) reported in a recent GWAS(16). In
153 addition, we included 38 AD risk variants meeting the same threshold from a recent AD GWAS
154 (17) (**Supplementary Table S1 & S2**) (**Fig. 1A**). We first investigated whether there was any
155 overlap between the two lists of susceptibility loci, and our results showed no direct overlap
156 between the top SNPs in the IBD and AD.
157

158 IBD and AD susceptibility loci have been reported to be enriched for genes expressed in peripheral
159 monocytes (10, 33, 34), which are mostly recent bone marrow immigrants that are relatively
160 undifferentiated. Myeloid cells adopt their final, functional states in tissue, in response to the local
161 environment, and thus we assessed whether the microglial state of differentiation would yield

162 differential enrichment for AD loci *vs.* the monocyte state. To do this, we downloaded monocyte
163 eQTL results (15) from the EMBL-EBI eQTL catalogue (14) (available at
164 https://www.ebi.ac.uk/eqtl/) and used microglia eQTLs sourced from our recent study (20). In this
165 study, we only kept the eSNP-eGene pairs with BH adjusted p-value<0.05, resulting in 925,472
166 monocyte eSNP-eGene pairs, and 100,578 microglia eSNP-eGene pairs. Integrating these results
167 with the disease susceptibility results show that >21.1% of AD (8/38) lead SNPs enriched among
168 microglia eQTLs (hypergeometric p-value = 1.17×10^{-8}). On the other hand, <2.5% of IBD (2/81),
169 CD (0/19), and UC (0/15) are microglia eSNPs (**Supplementary Table S4**). Different from
170 microglia, >19.7% of AD, IBD, CD and UC were monocyte eSNP (AD: hypergeometric p-value
171 = 2.18×10^{-5}, IBD: hypergeometric p-value = 5.20×10^{-4}, CD: hypergeometric p-value = 0.06, UC
172 hypergeometric p-value = 0.03) (**Supplementary Table S4**). Some of the difference in overlap
173 with AD loci between the monocyte and microglial eQTLs is likely to be due to the parent studies
174 given the smaller sample size and nuclear RNA-derived nature of the microglial data; both of these
175 factors will tend to diminish the number of eQTL discovered.
176
177 Integrating microlgia and monocyte eQTLs with the disease GWAS results, we uncovered
178 evidence of colocalization (PP.H4>0.8) for nine eGenes among nine AD loci within microglia (**Fig.
179 2A & Supplementary Table S5**). We confirm some of the well-validated results, such as *BIN1,*
180 *USP6NL* and *PICALM*. These microglial eQTLs colocalized with AD susceptibility were absent
181 in monocytes (35). On the contrary, only one eQTL target gene was found to be colocalized with
182 IBD risk variants (**Fig. 2B**) in microglia. ETS Proto-Oncogene 2 (*ETS2*), which plays a pivotal
183 role as a transcription factor driving inflammation in acutes and chronic inflammatory disease,
184 upregulation of genes with ETS2-binding sites has been previously reported in UC patients (36).

185

186 With respect to monocyte eQTLs, only two eGenes showed colocalization evidence in AD, they
187 are *APH1B* and *MADD*. Dysregulated expression levels of *APH1B* in peripheral blood were
188 reported associated with brain atrophy and amyloid-β deposition in Alzheimer's disease (37).
189 However, we identified seven monocyte eQTL effects colocalized with five IBD risk loci, three
190 colocalized with two CD risk loci, and five colocalized with five UC risk loci (**Fig. 2C & D,**
191 **supplementary Table S5**), For example, Scm Like With Four Mbt Domains 1 (*SFMBT1*) is a
192 polycomb protein with transcriptional repressor activity (38), and was identified as target genes
193 for IBD-associated variatns (39). ZFP90 Zinc Finger Protein (*ZFP90*), which has been reported to
194 drive the initiation of colitis-associated colorectal cancer (40). The dysregulation of *ZFP90* was
195 associated with some autoimmune diseases, including inflammatory bowel disease, vitiligo, and
196 multiple sclerosis (41).

197

198 **Genetic architecture of IBD and AD**

199 We then examined the impact of 81 genome-wide significant IBD risk loci on AD- and aging-
200 related pathological features by aggregating the effect of these variants into a wighted genetic risk
201 score (GRS) and then conducting an omnibus test, adjusting for age at death, sex and education,
202 which evaluates the distribution of the associations with ten pathologic endophenotypes (details
203 can be seen in **Fig. 3** legend and **Supplementary Table S3**). In this omnibus test, the distribution
204 of results for the individual pathologic traits is not significant, and none of the individual traits
205 reaches a threshold of nominal sifnificance (**Fig. 3A**). Expanding our analysis, we explored a CD
206 GRS and a UC GRS; the omnibus analyses for these GRS was also non-significant. However, we
207 noted a nominally significant (p-value<0.05) effect on cerebral amyloid angiopathy (CAA)

208 accumulation (p-value=0.02) (**Fig. 3B**), and the UC GRS demonstrated a significant association
209 with the extent of TDP-43 deposition (p-value=6.11×10^{-4}, FDR=6.11×10^{-3}) (**Fig. 3C**). The latter
210 result is the more intriguing one given its significance, and the fact that the biology of TDP-43
211 deposition remains less well understood.
212
213 To complement these analyses, we deployed a Phenome-wide association study (PheWAS)
214 approach to explore the associations between the IBD/CD/UC variants (exposure) and ten AD
215 endophenotypes (outcome) using the R PheWAS package (22), adjusting for age at death, sex and
216 education. Employing a linear regression model to accommodate numeric phenotype outcomes,
217 our results revealed that IBD had no significant effect on AD endophenotypes (**Fig. 3D**). While
218 CD displayed a nominally significant impact on cerebral amyloid angiopathy (beta=7.14, p-
219 value=0.02) (**Fig. 3E**), and UC demonstrated a notable effect on TDP-43 severity (beta=7.58, p-
220 value=6.11×10^{-4}, FDR=6.11×10^{-3}) (**Fig. 3F**). Based on the analyses above, our findings suggest
221 that CD risk loci may have a small contribution to CAA risk, whereas UC risk loci may have an
222 effect on TDP-43, consistent with the earlier analyses.
223
224 Subsequenctly, we utilized generalized summary statistics-based Mendelian randomization
225 (GSMR) (23) and two-sample Mendelian randomization (2SMR) (24) to investigate the causal
226 impact of IBD (exposure, N_{cases} =25,042; *Ncontrols*=34,915), CD (exposure, N_{cases} =12,194;
227 *Ncontrols*=28,072) and UC (exposure, N_{cases}=12,366; $N_{controls}$=33,609) on AD (outcome,
228 N_{cases}=90,338; *Ncontrols*=1,036,225) among individuals of European descent. Among these risk
229 variants, 78 out of 81 were found shared between IBD and AD summary statistics, 19 out of 19

230 were common between CD and AD summary statistics, and 15 out of 15 variants overlapped
231 between UC and AD summary statistics.
232
233 The results of mendian randomization indicated that genetically determined IBD was significantly
234 associated with a decreased susceptibility of AD (GSMR: b_{xy}=-4.76×10^{-3}, p-value=9.48×10^{-3},
235 Inverse variance-weighted (IVW): b_{xy}=-5.69×10^{-3}, p-value=0.03) (**Fig. 4A & D**). However, our
236 subanalyses indicated an increased causative relationship betweeen CD and AD (GSMR:
237 b_{xy}=9.83×10^{-3}, p-value=0.02, IVW: b_{xy}=0.01, p-value=0.02, weighted mean: b_{xy}=0.01, p-
238 value=0.01) (**Fig. 4B & E**), while UC exhibited no causal associations with AD (**Fig. 4C & F**)
239 (**Supplementary Table S6**).
240
241 **Genetic correlation between IBD and other traits**
242 Finally, we employed LD score regression (LDSC) (25) to estimate genetic correlations between
243 IBD and AD, along with other disease traits. To do this, we downloaded GWAS summary statistic
244 from nine previously published studies, which were all found to be enriched for loci encoding
245 myeloid genes. Including three IBD traits (IBD, CD and UC) (16), three neurodegenerative
246 disorders (AD (17), ALS (26) and Parkinson disease (PD) (27), another inflammatory disease
247 (Multiple sclerosis, MS (28)), a metabolic disease, type 2 diabetes (T2D) (29) and three psychiatric
248 disorders: bipolar disorder (BD) (30), major depressive disorder (MDD) (31) and schizophrenia
249 (SCZ) (32). **Fig. 5** inllustrates genetic correlations for all 55 pairwise combinations of these eleven
250 traits. To define significant genetic correlations, we adjusted for the number of traits tested, using
251 an FDR-corrected P-value threshold (FDR≤0.05).
252

253 Based on LDSC analysis, IBD-related traits showed no significant genetic correlation with AD,
254 ALS, PD and T2D. However, they displayed positive correlations with MS (FDR<=6.69×10^{-3}), as
255 expected given prior reports (42)), as well as with all psychiatric disorders (FDR<=0.01). In these
256 analyses, we found AD exhibited modest positive genetic correlations with ALS (FDR=0.01), BD
257 (FDR=0.04), PD (FDR=0.03), and T2D (FDR=0.04) (**see Supplementary Table S7**).
258

259 ## Discussion

260 Our study systematically assessed the potential shared genetic architecture between IBD and AD,
261 given that both sets of susceptibility loci display an enrichment for susceptibility genes expressed
262 in myeloid cells. Such shared architecture could significantly accelerate AD studies given the large
263 number of IBD loci. However, we found that, overall, AD risk variants are different from IBD risk
264 variants, and AD variants involve functional consequences that are primarily found in the the CNS-
265 specific myeloid context of microglia (43). Microglia are the resident macrophages of the CNS,
266 they play key roles in brain development and physiology during life and aging. By contrast,
267 patients with IBD reportedly have peripheral "monocytosis", an excess of monocytes that has been
268 proposed as a biomarker of severity in IBD (4); this cell type harbors several of the functional
269 cosnequences of IBD variants. Microglia and monocytes are ontogenetically distinct: while they
270 are both derived from the mesoderm, microglia derived from yolk-sac progenitors during
271 embryogenesis (44), whereas monocytes continuously differentiate throughout postnatal life from
272 bone marrow hematopoietic stem cells. Distinct developmental origin and renewal mechanisms
273 imply that monocyte-derived macrophages and microglia-derived macrophages that infiltrate
274 tissue, including the brain, may exert different functions in pathological processes.
275

276 While our examination of individual susceptibility loci revealed no sharing between AD and IBD,
277 our findings using more global approaches highlighted modest but intriguing evidence for a
278 genetically driven risk effect of IBD susceptibility on AD, which is consistent with earlier reports
279 (12, 13). In contrast, another previous study found no association between the risks of
280 neurodegenerative diseases and genetically predicted UC or CD (45), which may be due to the
281 smaller sample size of the IBD/CD/UC study used in this research. Overall, the effect of greater
282 CD or UC polygentic risk on cerebral amyloid angiopathy and TDP-43 severity, respectively, may
283 provide potential mechanistic hypotheses for the development of these neuropathologic features.
284
285 The genetic correlation of IBD with MS was consistent with previous reports, suggesting that our
286 rigorously applied methodology produce robust, expected results in the correct direction of effect
287 (46). Our results also showed significant positive genetic associations between IBD and psychiatric
288 disorders (BD, SCZ and MDD). Psychiatric comorbidity, including depression, anxiety, bipolar
289 disorder, and schizophrenia, is known to be more prevalent in IBD patients (47, 48).
290
291 Our study was motivated to evaluate the possibility of shared functional consequences of AD
292 variants in myeloid cells, which would have enabled us to accelerate the functional dissection of
293 innate immune perturbations that contributes to these two diagnostically distinct diseases. We
294 conclude that, while the two sets of variants target myeloid cell types, they cause largely distinct
295 perturbations expression, and there is only modest evidence that a genetic propensity for IBD
296 influences AD risk. The most intriguing result may be the connection of TDP-43 proteinopathy
297 with the variants included in the UC GRS; this provides insights into this pathophysiologic feature
298 that has pleiotropic manifestations, including connections to the ALS - Frontotemporal dementia

- cognitive aging spectrum. TDP-43 was identified as the major pathological protein in sporadic ALS and in the most common pathological subtype of FTD (49).In addition, the standardized incidence ratios for daughters for UC was found 2.02 when mothes were diagnosed with ALS (50). Notely, there is a strong genetic enrichment (160-fold) observed between FTD and UC (51), highlighting the complex interplay between these conditions and underscoring the need for more comprehensive studies.

References

1. Weiskopf K, Schnorr PJ, Pang WW, Chao MP, Chhabra A, Seita J, et al. Myeloid Cell Origins, Differentiation, and Clinical Implications. Microbiol Spectr. 2016;4(5).
2. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. Nat Rev Immunol. 2015;15(1):7-17.
3. Ramos GP, Papadakis KA. Mechanisms of Disease: Inflammatory Bowel Diseases. Mayo Clin Proc. 2019;94(1):155-65.
4. Anderson A, Cherfane C, Click B, Ramos-Rivers C, Koutroubakis IE, Hashash JG, et al. Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry. Inflamm Bowel Dis. 2022;28(1):70-8.
5. Gren ST, Grip O. Role of Monocytes and Intestinal Macrophages in Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis. 2016;22(8):1992-8.
6. Muller PA, Matheis F, Mucida D. Gut macrophages: key players in intestinal immunity and tissue physiology. Curr Opin Immunol. 2020;62:54-61.
7. Gopinath A, Collins A, Khoshbouei H, Streit WJ. Microglia and Other Myeloid Cells in Central Nervous System Health and Disease. J Pharmacol Exp Ther. 2020;375(1):154-60.
8. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018;217(2):459-72.
9. Garre-Olmo J. [Epidemiology of Alzheimer's disease and other dementias]. Rev Neurol. 2018;66(11):377-86.
10. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, et al. Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. Science. 2014;344(6183):519-23.
11. Fujita M, Gao Z, Zeng L, McCabe C, White CC, Ng B, et al. Cell subtype-specific effects of genetic variation in the Alzheimer's disease brain. Nat Genet. 2024;56(4):605-14.
12. Zingel R, Bohlken J, Kostev K. Association Between Inflammatory Bowel Disease and Dementia: A Retrospective Cohort Study. J Alzheimers Dis. 2021;80(4):1471-8.
13. Zhang B, Wang HE, Bai YM, Tsai SJ, Su TP, Chen TJ, et al. Inflammatory bowel disease is associated with higher dementia risk: a nationwide longitudinal study. Gut. 2021;70(1):85-91.

335 14. Kerimov N, Hayhurst JD, Peikova K, Manning JR, Walter P, Kolberg L, et al. A
336 compendium of uniformly processed human gene expression and splicing quantitative trait loci.
337 Nat Genet. 2021;53(9):1290-9.
338 15. Chen L, Ge B, Casale FP, Vasquez L, Kwan T, Garrido-Martin D, et al. Genetic Drivers
339 of Epigenetic and Transcriptional Variation in Human Immune Cells. Cell. 2016;167(5):1398-
340 414 e24.
341 16. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-
342 wide association study implicates immune activation of multiple integrin genes in inflammatory
343 bowel disease. Nat Genet. 2017;49(2):256-61.
344 17. Wightman DP, Jansen IE, Savage JE, Shadrin AA, Bahrami S, Holland D, et al. A
345 genome-wide association study with 1,126,563 individuals identifies new risk loci for
346 Alzheimer's disease. Nat Genet. 2021;53(9):1276-82.
347 18. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious
348 Orders Study and Rush Memory and Aging Project. J Alzheimers Dis. 2018;64(s1):S161-S89.
349 19. Shabalin AA. Matrix eQTL: ultra fast eQTL analysis via large matrix operations.
350 Bioinformatics. 2012;28(10):1353-8.
351 20. Fujita M, Gao Z, Zeng L, McCabe C, White CC, Ng B, et al. Cell-subtype specific effects
352 of genetic variation in the aging and Alzheimer cortex. Nature Genetics (in press). 2023.
353 21. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a
354 tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet.
355 2007;81(3):559-75.
356 22. Carroll RJ, Bastarache L, Denny JC. R PheWAS: data analysis and plotting tools for
357 phenome-wide association studies in the R environment. Bioinformatics. 2014;30(16):2375-6.
358 23. Zhu Z, Zheng Z, Zhang F, Wu Y, Trzaskowski M, Maier R, et al. Causal associations
359 between risk factors and common diseases inferred from GWAS summary data. Nat Commun.
360 2018;9(1):224.
361 24. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base
362 platform supports systematic causal inference across the human phenome. Elife. 2018;7.
363 25. Bulik-Sullivan B, Finucane HK, Anttila V, Gusev A, Day FR, Loh PR, et al. An atlas of
364 genetic correlations across human diseases and traits. Nat Genet. 2015;47(11):1236-41.
365 26. van Rheenen W, van der Spek RAA, Bakker MK, van Vugt J, Hop PJ, Zwamborn RAJ,
366 et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15
367 risk loci with distinct genetic architectures and neuron-specific biology. Nat Genet.
368 2021;53(12):1636-48.
369 27. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al.
370 Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a
371 meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18(12):1091-102.
372 28. International Multiple Sclerosis Genetics C. Multiple sclerosis genomic map implicates
373 peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460).
374 29. Spracklen CN, Horikoshi M, Kim YJ, Lin K, Bragg F, Moon S, et al. Identification of
375 type 2 diabetes loci in 433,540 East Asian individuals. Nature. 2020;582(7811):240-5.
376 30. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, et al.
377 Genome-wide association study of more than 40,000 bipolar disorder cases provides new
378 insights into the underlying biology. Nat Genet. 2021;53(6):817-29.

379 31. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shirali M, et al. Genome-
380 wide meta-analysis of depression identifies 102 independent variants and highlights the
381 importance of the prefrontal brain regions. Nat Neurosci. 2019;22(3):343-52.
382 32. Trubetskoy V, Pardinas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.
383 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature.
384 2022;604(7906):502-8.
385 33. Novikova G, Kapoor M, Tcw J, Abud EM, Efthymiou AG, Chen SX, et al. Integration of
386 Alzheimer's disease genetics and myeloid genomics identifies disease risk regulatory elements
387 and genes. Nat Commun. 2021;12(1):1610.
388 34. Baillie JK, Arner E, Daub C, De Hoon M, Itoh M, Kawaji H, et al. Analysis of the human
389 monocyte-derived macrophage transcriptome and response to lipopolysaccharide provides new
390 insights into genetic aetiology of inflammatory bowel disease. PLoS Genet.
391 2017;13(3):e1006641.
392 35. Lopes KP, Snijders GJL, Humphrey J, Allan A, Sneeboer MAM, Navarro E, et al.
393 Genetic analysis of the human microglial transcriptome across brain regions, aging and disease
394 pathologies. Nat Genet. 2022;54(1):4-17.
395 36. van der Pouw Kraan TC, Zwiers A, Mulder CJ, Kraal G, Bouma G. Acute experimental
396 colitis and human chronic inflammatory diseases share expression of inflammation-related genes
397 with conserved Ets2 binding sites. Inflamm Bowel Dis. 2009;15(2):224-35.
398 37. Park YH, Pyun JM, Hodges A, Jang JW, Bice PJ, Kim S, et al. Dysregulated expression
399 levels of APH1B in peripheral blood are associated with brain atrophy and amyloid-beta
400 deposition in Alzheimer's disease. Alzheimers Res Ther. 2021;13(1):183.
401 38. Wu S, Trievel RC, Rice JC. Human SFMBT is a transcriptional repressor protein that
402 selectively binds the N-terminal tail of histone H3. FEBS Lett. 2007;581(17):3289-96.
403 39. Hulur I, Gamazon ER, Skol AD, Xicola RM, Llor X, Onel K, et al. Enrichment of
404 inflammatory bowel disease and colorectal cancer risk variants in colon expression quantitative
405 trait loci. BMC Genomics. 2015;16(1):138.
406 40. Han JX, Tao ZH, Qian Y, Yu CY, Li J, Kang ZR, et al. ZFP90 drives the initiation of
407 colitis-associated colorectal cancer via a microbiota-dependent strategy. Gut Microbes.
408 2021;13(1):1-20.
409 41. Morris DL, Sheng Y, Zhang Y, Wang YF, Zhu Z, Tombleson P, et al. Genome-wide
410 association meta-analysis in Chinese and European individuals identifies ten new loci associated
411 with systemic lupus erythematosus. Nat Genet. 2016;48(8):940-6.
412 42. Cotsapas C, Mitrovic M. Genome-wide association studies of multiple sclerosis. Clin
413 Transl Immunology. 2018;7(6):e1018.
414 43. Hemonnot AL, Hua J, Ulmann L, Hirbec H. Microglia in Alzheimer Disease: Well-
415 Known Targets and New Opportunities. Front Aging Neurosci. 2019;11:233.
416 44. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, et
417 al. A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science.
418 2012;336(6077):86-90.
419 45. Li H, Wen Z. Effects of ulcerative colitis and Crohn's disease on neurodegenerative
420 diseases: A Mendelian randomization study. Front Genet. 2022;13:846005.
421 46. Yang Y, Musco H, Simpson-Yap S, Zhu Z, Wang Y, Lin X, et al. Investigating the
422 shared genetic architecture between multiple sclerosis and inflammatory bowel diseases. Nat
423 Commun. 2021;12(1):5641.

424 47. Marrie RA, Walld R, Bolton JM, Sareen J, Walker JR, Patten SB, et al. Increased
425 incidence of psychiatric disorders in immune-mediated inflammatory disease. J Psychosom Res.
426 2017;101:17-23.
427 48. Bernstein CN, Hitchon CA, Walld R, Bolton JM, Sareen J, Walker JR, et al. Increased
428 Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis.
429 2019;25(2):360-8.
430 49. Mackenzie IR, Rademakers R. The role of transactive response DNA-binding protein-43
431 in amyotrophic lateral sclerosis and frontotemporal dementia. Curr Opin Neurol.
432 2008;21(6):693-700.
433 50. Hemminki K, Li X, Sundquist J, Sundquist K. Familial risks for amyotrophic lateral
434 sclerosis and autoimmune diseases. Neurogenetics. 2009;10(2):111-6.
435 51. Broce I, Karch CM, Wen N, Fan CC, Wang Y, Tan CH, et al. Immune-related genetic
436 enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS
437 Med. 2018;15(1):e1002487.
438

439 Acknowledgements

440 We thank all the participants of the ROS/MAP study, the BLUEPRINT study, and the IBD GWAS
441 and AD GWAS for their participation and generous donations.

442 Funding

443 This study was supported by NIH grants (ROSMAP is supported by P30AG10161, P30AG72975,
444 R01AG15819, R01AG17917, U01AG46152, U01AG61356; ROSMAP resources can be
445 requested at https://www.radc.rush.edu).

446 Author information

447 Center for Translational and Computational Neuroimmunology, Department of Neurology and the
448 Taub Institute for Research on Alzheimer's disease and the Aging brain, Columbia University
449 Irving Medical Center, New York, NY, USA.
450 Lu Zeng, Charles C. White, Hans-Ulrich Klein, Philip L. De Jager
451 Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
452 David A. Bennett

453 Corresponding author

Correspondence to Philip L. De Jager.

Author Contributions

LZ and PLD concept and designed the study; LZ performed the research; CCW provided data and code contributed to the analyses; HUK and DAB participated in the discussion and interpretation of the results; LZ and PLD wrote the paper; LZ created the figures which were edited by PLD; All the authors reviewed and revised the paper.

Ethics declarations

Competing interests

The authors declare no competing interests.

477 ## Figure legends

478 **Fig. 1. Overview of AD and IBD risk variants used in this study.**
479 **A)** Manhattan plot of 38 genome-wide significant ($p<=5 \times 10^{-8}$) AD risk variants and 81/19/15
480 genome-wide significant ($p<=5 \times 10^{-8}$) IBD/CD/UC risk variants extracted from previous studies.
481 **Fig. 2. Colocalization between IBD/UC/CD/AD risk variants and microglia/monocyte eQTLs.**
482 A) Example of eQTL-AD-GWAS colocalization near the *RABEP1* locus in microglia.
483 B) Example of eQTL-IBD-GWAS colocalization near the *ETS2* locus in microglia.
484 C) Example of eQTL-CD-GWAS colocalization near the *SFMBT1* locus in monocyte.
485 D) Example of eQTL-UC-GWAS colocalization near the *ZFP90* locus in monocyte.
486 **Fig. 3. Genetic analysis between IBD and AD endophenotypes**
487 A) The impact of IBD risk on AD endophenotypes (e.g. amyloid, plaque and tangles)**.** Each dot
488 represents a ROSMAP AD endophenotype and its expected and observed associations with AD
489 endophenotype. The expected P values assume a null distribution with no linear associations
490 between IBD risk score and AD pathologies after adjusting age at death, sex and education. The
491 gray and dark areas indicate the extreme ranges of the QQ plot as generated by chance at a
492 threshold of P=0.05 and P=0.10, respectively. The 95% and 90% confidence intervals were
493 empirically derived by randomly assigning participants with the IBD risk score and repeating the
494 analysis 1,000 times. Based on the distribution of the observed P values for all the ten AD
495 phenotypes.
496 B) Phenome-wide association plots of IBD risk with the ROSMAP AD endophenotypes. Each dot
497 represents a ROSMAP AD endophenotypes, the red line is the p-value threshold ($p \leq 0.05$). The
498 effect size denotes the beta value.
499 **Fig. 4. Scatter plots of MR analyses showing the causal effects of IBD on AD**. Six different
500 methods, including: Generalised Summary-data-based Mendelian Randomisation (GSMR),
501 default inverse variance-weighted (IVW), weighted mode, weighted median, Mendelian
502 randomization-Egger (MR-Egger) regression and simple median were used to evaluate the causal
503 effects of IBD (UC and CD) on AD. The slope in each line represents the causal estimate of an
504 exposure on corresponding outcome per method. (A, D) SNP's effect on IBD and AD; (B, E)
505 SNP's effect on CD and AD; (C, F) SNP's effect on UC and AD.
506

507 **Fig. 5. Genetic correlation between neurological and inflammatory diseases**

508 Genetic correlation estimates across 11 human diseases. The areas of the squares represent the
509 absolute value of corresponding genetic correlations. After FDR correction at 5% significance
510 level, genetic correlations estimate that are significantly different from zero are marked with an
511 asterisk (* 0.01<FDR<=0.05; ** 0.001 <FDR<=0.01; *** FDR<=0.001). The blue color denotes
512 a positive genetic correlation, the red color denotes a negative genetic correlation.

513


38 AD SNPs
APOE
rs429358
-log10(p-value)
300
200
100
60
40
20
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
IL23R
rs11581607
81 IBD SNPs
19 CD SNPs
15 UC SNPs


Microglia eQTLs
A
AD-GWAS
rs58124010
-log10(p.GWAS)
B
IBD-GWAS
rs2836881
r2
0.8
0.6
0.4
0.2
eQTL-RABEP1
rs58124010
-log10(p.eQTL)
chr17 (Mb)
eQTL-ETS2
rs2836881
chr21 (Mb)
Monocyte eQTLs
C
CD-GWAS
rs2581828
-log10(p.GWAS)
D
UC-GWAS
rs1728785
eQTL-SFMBT1
rs2581828
-log10(p.eQTL)
chr3 (Mb)
eQTL-ZFP90
rs1728785
chr16 (Mb)


A
IBD risk score
95% CI
90% CI
Observed
Expected
B
CD risk score
95% CI
90% CI
Observed
Expected
C
UC risk score
95% CI
90% CI
Observed
Expected
D
−log10(p−value)
AD endophenotypes
Effect size
−5
0
5
E
caa_neo4
−log10(p−value)
AD endophenotypes
Effect size
−2.5
0.0
2.5
5.0
F
tdp_cs_6reg
−log10(FDR)
AD endophenotypes
Effect size
0
2
4
6
Category
amyloid_sqrt
caa_neo4
cogng_demog_slope
cogres.path.no_tdp
cogres.path.tdp
nft_sqrt
plaq_d_sqrt
plaq_n_sqrt
tangles_sqrt
tdp_cs_6reg


MR Test
GSMR
Inverse variance weighted
MR Egger
Simple mode
Weighted median
Weighted mode
A
bxy =−0.005
p−value = 0.009
B
bxy =0.010
p−value = 0.017
C
bxy =2.217E-04
p−value = 0.953
SNP effect on AD
D
E
F
SNP effect on IBD
SNP effect on CD
SNP effect on UC


CD
UC
AD
ALS
BD
MDD
MS
PD
SCZ
T2D
IBD
CD
UC
AD
ALS
BD
MDD
MS
PD
SCZ
1
0.8
0.6
0.4
0.2
0
-0.2
-0.4
-0.6
-0.8
-1